Features | Partner Sites | Information | LinkXpress
Sign In
Biostrata Ltd on behalf of Thermo
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Combined Spectroscopy System Rapidly Scans Skin Lesions for Cancer Signs

By Labmedica International staff writers
Posted on 19 Aug 2014
Image: The photo on the left shows the entire three-in-one spectroscopy system on an easily transportable utility cart. The right photo is a close-up of the probe (Photo courtesy of the University of Texas, Austin).
Image: The photo on the left shows the entire three-in-one spectroscopy system on an easily transportable utility cart. The right photo is a close-up of the probe (Photo courtesy of the University of Texas, Austin).
A team of biomedical engineers has designed an instrument for the rapid diagnosis of skin cancer that does not rely on examination of biopsy specimens.

Skin cancer is detected currently by examining biopsy specimens. However, statistics suggest that for every case of skin cancer detected there are roughly 25 negative biopsies performed. To correct this situation, investigators at the University of Texas, Austin (USA) combined three advanced spectroscopy instruments into a single tool for scanning skin lesions and detecting changes in the way that skin tissues interact with light when normal skin becomes cancerous with enlarged cell nuclei and disorganization of the uppermost layers of the skin.

The multimodal spectroscopy (MMS) device characterizes the tissue microenvironment via morphological changes observed through DRS (diffuse reflectance spectroscopy) and biochemical information via RS (Raman spectroscopy) and LIFS (laser-induced fluorescence spectroscopy).

The DRS measurement is a function of tissue scattering and absorption properties, which in turn are dependent upon tissue morphological changes. Therefore, analysis yields information about tissue blood fraction, oxygen saturation, tissue scattering coefficient, nuclear morphology, and collagen structure. LIFS is biochemically sensitive, as it interrogates endogenous fluorophores such as nicotinamide adenine dinucleotide (NADH), flavin adenine dinucleotide (FAD), and collagen. Their fluorescence levels change with cancer progression that is associated with altered cellular metabolic pathways (NADH, FAD) or an altered structural tissue matrix (collagen). Raman spectroscopy exploits the inelastic scattering (so-called “Raman” scattering) phenomena to detect spectral signatures of important disease progression biomarkers, including lipids, proteins, and amino acids.

The spectroscopic and computer equipment required by the system fits onto a portable utility cart, and the probe is about the size of a pen. Each reading takes about 4.5 seconds to perform.

"Skin is a natural organ to apply imaging and spectroscopy devices to because of its easy access," said senior author Dr. James W. Tunnell, associate professor of biomedical engineering at the University of Texas, Austin. Most devices have been at the research stage for the last 10 years or so, but several are now undergoing clinical development. This probe that is able to combine all three spectral modalities is the next critical step to translating spectroscopic technology to the clinic."

A detailed description of the MMS device was published in the August 5, 2014, online edition of the journal Review of Scientific Instruments.

Related Links:
University of Texas, Austin


CELLAVISION AB
KARL HECHT GMBH & CO KG
EUROIMMUN AG
WATERS CORPORATION

Channels

Clinical Chemistry

view channel
Image: The Avance III 600 spectrometer for proton nuclear magnetic resonance analysis (Photo courtesy of Bruker).

New Blood Test Can Predict Future Breast Cancer

The analysis of a blood sample could predict if a woman will get breast cancer within two to five years which could create a paradigm shift in early diagnosis of this malignant neoplasm as well as other diseases.... Read more

Genetic Tests

view channel

Buccal Swabs Replace Phlebotomy for Postnatal and Pediatric DNA Collection

Collection of samples for prenatal and pediatric DNA sequencing procedures is now available via buccal swabs rather than by phlebotomy. CombiMatrix Corporation (Irvine, CA, USA) a molecular diagnostics company specializing in DNA-based diagnostic services for prenatal, postnatal, and pre-implantation genetic testing... Read more

Hematology

view channel
Image: The new point-of-care Hemo Control delivers laboratory-accurate hemoglobin and hematocrit results in one simple test and uniquely offers flexible and enhanced data management with bi-directional interface (Photo courtesy of EKF Diagnostics).

Next-Generation Hemoglobin Analyzer Uniquely Ensures Bi-Directional Data Management Future Proofing

A new point-of-care (POC) diagnostics analyzer delivers quantitative laboratory-accurate hemoglobin and hematocrit results in one simple test and uniquely enables upgrade with data management functionality... Read more

Industry News

view channel

Main Factors Driving Revenue Growth in Clinical Chemistry Identified

According to a report by Kalorama Information (New York, NY, USA), overall growth in the clinical chemistry market will be modest, driven mainly by new tests and demographic changes, including an aging population and increasing number of people at risk of cardiovascular disease, such as those with hypertension, diabetes... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.